Cited by 4,917Antifungal resistance and susceptibilityFungal Infections and StudiesNeutropenia and Cancer Infections

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Open access
De Pauw, Ben, Walsh, Thomas J., Donnelly, J. Peter, Stevens, David A., Edwards, John E., Calandra, Thierry, Pappas, Peter G., Maertens, Johan +24 more·2008·Clinical Infectious Diseases

Abstract

BACKGROUND: Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. METHODS: After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. RESULTS: The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. CONCLUSIONS: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/588660

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The development of standardized diagnostic criteria for invasive aspergillosis has been a major improvement for IPA.

    “The development of standardized diagnostic criteria for invasive aspergillosis has been a major improvement for IPA (94).”

    From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [94]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Goodman JS, Kaufman L, Koenig MG. Diagnosis of cryptococcal men- ingitis: value of immunologic detection of cryptococcal antigen. N Engl J Med 1971; 285:434-6.
  2. Obayashi T, Yoshida M, Mori T, et al. Plasma (1r3)-b-d-glucan mea- surement in diagnosis of invasive deep mycosis and fungal febrile ep- isodes. Lancet 1995; 345:17-20.

Cited by

Sorted by citations

Authors
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., Denning, D. W., Patterson, T. F., Maschmeyer, G., Bille, J., Dismukes, W. E., Herbrecht, R., Hope, W. W., Kibbler, C. C., Kullberg, B. J., Marr, K. A., Muñoz, P., Odds, F. C., Perfect, J. R., Restrepo, A., Ruhnke, M., Segal, B. H., Sobel, J. D., Sorrell, T. C., Viscoli, C., Wingard, J. R., Zaoutis, T., & Bennett, J. E.
Affiliations
Radboud University Medical Center (NL)
Corresponding author
Donnelly, J. Peter
Venue
Clinical Infectious Diseases
Published
2008-06-15
Volume
46
Issue
12
Pages
1813-1821
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2166734004
Cited by
4,917
References
28
Citations by year
2026: 85 · 2025: 146 · 2024: 169 · 2023: 172 · 2022: 203 · 2021: 280 · 2020: 362 · 2019: 424 · 2018: 383 · 2017: 354 · 2016: 345 · 2015: 376 · 2014: 363 · 2013: 299 · 2012: 279
FWCI
140.34
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Repository University of Antioquia (University of Antioquia) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion)
  • IRIS (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
  • Amgen
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Gilead Sciences
  • Children's Hospital of Philadelphia
  • Wayne State University
  • University of Pennsylvania
  • Wellcome Trust
  • Valeant Pharmaceuticals International
  • European Commission
  • University of Aberdeen
  • European Organisation for Research and Treatment of Cancer
  • Astellas Pharma
  • Centre Hospitalier Universitaire Vaudois
  • Basilea Pharmaceutica
  • Italfarmaco
  • National Institutes of Health
  • University at Buffalo
  • Medical School, University of Michigan
  • University of Texas Health Science Center at San Antonio
  • Medical Research Council
  • National Health and Medical Research Council
  • National Institute of Allergy and Infectious Diseases (Z01AI000654)
  • Janssen Pharmaceuticals
  • UCB Pharma
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
Keywords
invasive fungal infections, diagnostic definitions, immunocompromised patients, clinical trial endpoints, fungal epidemiology
MeSH terms
Humans, Mycoses, Terminology as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review